20-hydroxy-5,8,11,14-eicosatetraenoic acid has been researched along with rofecoxib in 3 studies
| Studies (20-hydroxy-5,8,11,14-eicosatetraenoic acid) | Trials (20-hydroxy-5,8,11,14-eicosatetraenoic acid) | Recent Studies (post-2010) (20-hydroxy-5,8,11,14-eicosatetraenoic acid) | Studies (rofecoxib) | Trials (rofecoxib) | Recent Studies (post-2010) (rofecoxib) |
|---|---|---|---|---|---|
| 640 | 13 | 233 | 1,914 | 307 | 163 |
| Protein | Taxonomy | 20-hydroxy-5,8,11,14-eicosatetraenoic acid (IC50) | rofecoxib (IC50) |
|---|---|---|---|
| Prostaglandin G/H synthase 2 | Bos taurus (cattle) | 0.43 | |
| Cytochrome c oxidase subunit 2 | Homo sapiens (human) | 1.51 | |
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | 0.5 | |
| Seed linoleate 13S-lipoxygenase-1 | Glycine max (soybean) | 0.5 | |
| Calpain-2 catalytic subunit | Homo sapiens (human) | 0.02 | |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | 1.8 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 0.3602 | |
| Prostaglandin G/H synthase 2 | Rattus norvegicus (Norway rat) | 0.76 | |
| Prostaglandin G/H synthase 2 | Ovis aries (sheep) | 0.486 | |
| Prostaglandin G/H synthase 2 | Mus musculus (house mouse) | 0.036 | |
| Sodium-dependent serotonin transporter | Macaca mulatta (Rhesus monkey) | 0.5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ai, D; Chiamvimonvat, N; Hammock, BD; Li, N; Liu, JY; Qiu, H; Yang, J; Zhu, Y | 1 |
| Ergul, A; Hoda, MN; Li, W; Luo, P; Maddipati, KR; Seki, T; Wang, MH; Zhang, Y; Zheng, X | 1 |
| Aghazadeh-Habashi, A; Asghar, W; Jamali, F | 1 |
3 other study(ies) available for 20-hydroxy-5,8,11,14-eicosatetraenoic acid and rofecoxib
| Article | Year |
|---|---|
Metabolic profiling of murine plasma reveals an unexpected biomarker in rofecoxib-mediated cardiovascular events.
Topics: Animals; Biomarkers; Bleeding Time; Blood Coagulation; Blood Platelets; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Hydroxyeicosatetraenoic Acids; Lactones; Male; Mice; Mice, Inbred C57BL; Platelet Aggregation; Sulfones | 2010 |
Combined therapy with COX-2 inhibitor and 20-HETE inhibitor reduces colon tumor growth and the adverse effects of ischemic stroke associated with COX-2 inhibition.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Ischemia; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cytochrome P-450 CYP4A; Dinoprostone; Humans; Hydroxyeicosatetraenoic Acids; Lactones; Male; Mice; Mice, Inbred C57BL; Rats; Stroke; Sulfones; Time Factors; Tumor Burden | 2014 |
Drug-Disease Interaction: Effect of Inflammation and Nonsteroidal Anti-Inflammatory Drugs on Cytochrome P450 Metabolites of Arachidonic Acid.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Arthritis, Experimental; Celecoxib; Cytochrome P-450 Enzyme System; Heart; Hydroxyeicosatetraenoic Acids; Inflammation; Kidney; Lactones; Male; Meloxicam; Rats; Rats, Sprague-Dawley; Sulfones; Thiazines; Thiazoles | 2018 |